Unichem Laboratories Ltd Stock Hits 52-Week Low at Rs.398

Stock Price Movement and Market Context

On 19 Jan 2026, Unichem Laboratories Ltd’s stock price touched Rs.398, the lowest level recorded in the past year. This new low comes after two consecutive days of declines, during which the stock lost 2.46% in returns. Despite this, the stock marginally outperformed its sector by 0.36% on the day. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure.

In comparison, the Sensex opened flat but later declined by 525.47 points, or 0.72%, closing at 82,969.02. The benchmark index remains 3.84% shy of its 52-week high of 86,159.02, and has experienced a three-week consecutive fall, losing 3.26% over that period. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating mixed technical signals for the broader market.

Long-Term Performance and Relative Returns

Over the last twelve months, Unichem Laboratories Ltd has delivered a total return of -43.80%, significantly underperforming the Sensex, which posted an 8.29% gain over the same period. The stock’s 52-week high was Rs.785.85, highlighting the extent of the decline. Additionally, the company’s performance has lagged behind the BSE500 index across multiple time frames, including the last three years, one year, and three months, reflecting persistent challenges in maintaining market momentum.

Financial Metrics and Credit Profile

Unichem Laboratories Ltd’s financial indicators reveal areas of concern that have contributed to the stock’s subdued performance. The company’s Debt to EBITDA ratio stands at 4.87 times, indicating a relatively high leverage level and a constrained ability to service debt obligations efficiently. The debt-equity ratio at the half-year mark is 0.21 times, the highest recorded recently, underscoring increased reliance on borrowed funds.

Interest expenses for the quarter rose by 25.99% to Rs.8.24 crores, further pressuring profitability. Non-operating income constitutes 44.20% of the company’s profit before tax, suggesting that core business earnings are supplemented significantly by ancillary income streams rather than operational strength alone.

Profitability and Growth Trends

Return on Equity (ROE) averaged at a modest 1.44%, reflecting limited profitability generated per unit of shareholders’ funds. Net sales have grown at an annual rate of 12.60% over the past five years, which is relatively subdued for the pharmaceuticals sector. However, operating profit has exhibited a healthier compound annual growth rate of 37.55%, indicating some improvement in operational efficiency or cost management.

The company’s Return on Capital Employed (ROCE) is 4.9%, and it maintains an enterprise value to capital employed ratio of 1.2, which is considered very attractive from a valuation standpoint. Despite the stock’s negative returns, profits surged by 419.9% over the past year, resulting in a low PEG ratio of 0.1, which typically signals undervaluation relative to earnings growth.

Shareholding and Market Sentiment

The majority shareholding remains with promoters, indicating stable ownership structure. The company’s Mojo Score is 40.0, with a Mojo Grade of Sell, downgraded from Hold on 22 Jul 2025. The market capitalisation grade is 3, reflecting mid-tier valuation metrics within its sector.

Summary of Key Factors Influencing the 52-Week Low

The stock’s decline to Rs.398 is underpinned by a combination of financial and market factors. Elevated leverage ratios and rising interest costs have weighed on profitability metrics, while sales growth has remained moderate relative to sector peers. The stock’s valuation metrics suggest it is trading at a discount, yet the low returns and downgraded Mojo Grade reflect caution in the market’s assessment of the company’s near-term prospects.

Despite the broader market’s mixed signals, with the Sensex itself experiencing a recent decline, Unichem Laboratories Ltd’s underperformance is more pronounced, highlighting company-specific pressures. The stock’s position below all major moving averages further emphasises the prevailing bearish sentiment among market participants.

Conclusion

Unichem Laboratories Ltd’s fall to a 52-week low of Rs.398 marks a significant point in its recent market journey. The combination of subdued sales growth, high leverage, and modest profitability has contributed to the stock’s underwhelming performance relative to the broader market and sector indices. While valuation metrics indicate a discount, the company’s financial profile and recent grading changes reflect ongoing challenges that have influenced investor sentiment and stock price movement.

Unlock special upgrade rates for a limited period. Start Saving Now →